Occident | Activity | F4Occident Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Investment
Participated in Immitra Bio's CHF 2.4M Pre-Seed round for an in-vivo gene therapy platform for rare genetic diseases.
Immitra Bio
Portfolio company Tubulis entered a definitive acquisition agreement with Gilead.
Investment
Participated in Tubulis' >€300M Series C, led by Venrock Healthcare Capital Partners, to advance antibody-drug conjugate development.
Tubulis
News
Team strategy retreat in the Austrian Alps to strengthen firm strategy and team cohesion.
OCCIDENT team retreat in the Austrian Alps
Milestone
Thermosome reported promising Phase 1 efficacy and safety data for THE001, supporting progression to Phase 2 in advanced soft-tissue sarcoma.
Thermosome
Milestone
ReCatalyst established a strong advisory board of four international industry experts ahead of its next growth phase.
ReCatalyst
News
Hosted the fifth OCCIDENT Pitch Event in Munich, featuring 18 startups nominated by OCCIDENT, the Helmholtz Association, and xista science ventures.
OCCIDENT Pitch Event, 5th edition, Munich
Milestone
Algiax presented promising Phase 2 results for lead compound AP-325 in peripheral postoperative neuropathic pain, showing reduced side effects.
Algiax Pharmaceuticals
Milestone
Tubulis advanced its second drug candidate, TUB-030, a next-generation ADC, into Phase I/IIa clinical evaluation for advanced solid tumors.
Tubulis
3 exits· JAN 2014 – SEP 2023Show all
Exit
Portfolio company adivo was acquired by animal health company Zoetis.
adivo acquired by Zoetis
Exit
Portfolio company Cunesoft was successfully exited.
Cunesoft exit
Exit
Portfolio company Kooaba, an image-recognition startup, was acquired by Qualcomm.
Kooaba acquired by Qualcomm